INVZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Innoviz Technologies is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows some near-term pre-market strength, but the broader setup is still weak: technicals are neutral, analysts recently cut their rating and price target, and there is no fresh news catalyst. The business is growing revenue sharply, but losses remain large. My direct view: hold off on buying now.
INVZ is in a mixed-to-neutral technical position. Pre-market price is 0.708, up 5.66%, but the current price of 0.6701 remains close to the pivot at 0.672. RSI_6 at 50.534 is neutral, MACD histogram is slightly positive at 0.00832 but contracting, and moving averages are converging, which points to a sideways-to-uncertain trend rather than a strong uptrend. Key levels to watch are resistance at 0.727 and 0.76, with support at 0.618 and 0.584. The stock trend model suggests a small near-term downside and only modest monthly upside.
["Pre-market price is up 5.66%, showing immediate trader interest.", "Revenue in 2025/Q4 increased 110.29% YoY, indicating strong top-line growth.", "Gross margin improved sharply to 16.29%, up 82.21% YoY.", "Options positioning is bullish, with extremely low put-call ratios.", "No recent negative news was reported in the last week."]
["Goldman Sachs downgraded the stock to Neutral from Buy and cut the price target to $0.75 from $1.25.", "Analysts said competitor momentum and weak conversion of the SODW into a series production award are concerns.", "Net income remains deeply negative at -21.255 million, and EPS is still negative.", "No recent news catalysts were available in the past week.", "Hedge funds and insiders are both neutral with no meaningful accumulation signals.", "No recent congress trading data is available."]
In 2025/Q4, Innoviz posted strong revenue growth of 110.29% YoY to $12.674 million, and gross margin improved materially to 16.29% YoY. However, profitability remains weak, with net income still at -$21.255 million and EPS at -0.10. The latest quarter shows improving operating scale, but the company is not yet profitable.
Analyst sentiment has turned less favorable. On 2026-04-13, Goldman Sachs downgraded Innoviz to Neutral from Buy and cut the price target to $0.75 from $1.25, citing better momentum at competitors and concern that expected OEM award conversion has not materialized. On 2026-04-14, Goldman reiterated Neutral and lowered the target again to $0.75, saying auto OEMs and suppliers may face softer results. Overall Wall Street pros/cons view: pros are growth potential in automotive lidar and improving fundamentals; cons are weak execution visibility, lack of confirmed awards, and continued losses.
